The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.
After a public hearing to amend the zoning ordinance regarding access control, parking and site plan requirements with no opposition from the public, the Soddy Daisy Commission gave the second and ...